French prosecutors and gendarmerie have sent 22 people to trial in Paris over an alleged fraud scheme involving health insurers, optical businesses, insured customers and ophthalmologists. The alleged system used prescriptions and reimbursement claims to turn unjustified insurance compensation into credit for optical products, with the suspected annual value put at €12m.
How the alleged reimbursement scheme worked
According to the Paris prosecutor and gendarmerie, optical staff directed some customers to cooperating ophthalmologists, who sometimes issued prescriptions without examining the patient. Those prescriptions allegedly enabled customers to obtain reimbursement for glasses or other optical products beyond what was justified. The reimbursement was then converted into credit for goods, particularly luxury frames and sunglasses. Customers received glasses suited to their needs, while expensive and unnecessary products were reportedly kept in specialist storage. The arrangement therefore depended on several connected roles: the prescription, the insurance claim, the optical sale and the allocation of goods.
A commercial advantage built into the alleged model
The alleged practice did more than create an improper payment claim. Gendarmerie investigators say it allowed participating optical workers to increase the volume of their business and strengthen their competitive position, while ophthalmologists involved benefited from a larger flow of patients. Some optical workers reportedly admitted that more than half of their turnover was based on the alleged fraud. The case shows why reimbursement systems can affect competition between suppliers: where compensation is linked to prescribed or purchased goods, false clinical input can distort demand, shift business towards cooperating outlets and leave insurers paying for products that were not medically or commercially justified.
Investigation reaches businesses and professional bodies
The preliminary investigation began in 2025 after reports from health insurance companies and was assigned to the Central Office for the Suppression of Illegal Employment. Searches took place from January to July 2026 at optical shops, health centres and ophthalmology practices. Those sent to trial include two ophthalmologists, ten optical workers and three chairmen of healthcare associations. Fifteen legal entities are also involved, including five ophthalmology centres. Eleven people were placed under judicial supervision, including restrictions on running a company or chairing an association. No allegation in the case has been proved by a court.
Trial, confiscation and possible wider action
The Paris trial is expected to take place from 3 to 15 June 2027. Those facing proceedings could receive prison sentences of up to ten years, and assets including optical equipment valued at €1.3m may be confiscated. The gendarmerie said the investigation may extend beyond the case due to be heard in June, alleging that the suspected scheme is widespread and estimating its scale in the Paris region at about €250m since 2023. Prosecutors have passed material to the competent authorities, opening the way to tax recovery, possible removal of involved doctors from France’s health insurance lists and potential disciplinary action by the medical bodies.
| Fact | Details |
|---|---|
| People sent to trial | 22 |
| Legal entities involved | 15 |
| Alleged annual value | €12m |
| Expected trial dates | 3–15 June 2027 |
| Assets potentially subject to confiscation | Optical equipment valued at €1.3m |
| People under judicial supervision | 11 |
| Estimated Paris-region scale since 2023 | About €250m |
An organised fraud and money-laundering system involving insured people, optical workers and prescribing doctors, according to Paris prosecutor Laure Beccuau.
WHY IT MATTERS
Health-insurance reimbursement can operate like a purchasing route: a prescription creates eligibility, an optical business supplies the goods and the insurer pays or provides credit. The alleged conduct shows how false clinical evidence and coordinated supplier activity can undermine that route, distort competition and expose public or compulsory insurance funds to claims for products that were not justified.
Reported from lrytas.lt, 2026-09-28. The Tender Wire is published by Otnox.
